Quick answers
- What is Buprenorphine Transdermal System?
- Buprenorphine Transdermal System is a brand name of Buprenorphine, a prescription medicine. The FDA NDC Directory lists 5 Buprenorphine Transdermal System products in 4 strengths and forms.
- Who makes Buprenorphine Transdermal System?
- Strides Pharma Intl holds the FDA application for Buprenorphine Transdermal System (ANDA207490, approved May 17, 2022). 1 other company (repackagers or distributors) also list Buprenorphine Transdermal System products.
- Is there a generic or store brand of Buprenorphine Transdermal System?
- Yes. The FDA NDC Directory lists 20 other products with the same active ingredients, strength and form as a Buprenorphine Transdermal System product, 16 of them generic. Ask your pharmacist whether one is right for you.
- What do pharmacies pay for Buprenorphine Transdermal System?
- CMS lists a National Average Drug Acquisition Cost (NADAC) for 1 Buprenorphine Transdermal System strength and form (see the table below). That is what pharmacies pay to buy it, not what you pay: your price depends on your insurance and your pharmacy.
- Has Buprenorphine Transdermal System been recalled?
- No recall linked to Buprenorphine Transdermal System products (by their NDC code or label) appears in the FDA enforcement reports we use.
What Buprenorphine Transdermal System is
Each Buprenorphine Transdermal System product as listed in the FDA NDC Directory, by active ingredient, strength and form, with its official label. “Same medicine, other names” counts the other products with exactly the same active ingredients, strength and form (generic versions, store brands and other brands); inactive ingredients can differ.
Buprenorphine · prescription medicine
| Strength and form | Product names | Same medicine, other names | Label |
|---|---|---|---|
| buprenorphine 10 ug/h patch, extended release (transdermal) | Buprenorphine Transdermal System | 5 products, 5 companies | DailyMed |
| buprenorphine 15 ug/h patch, extended release (transdermal) | Buprenorphine Transdermal System | 5 products, 5 companies | DailyMed |
| buprenorphine 20 ug/h patch, extended release (transdermal) | Buprenorphine Transdermal System | 5 products, 5 companies | DailyMed |
| buprenorphine 5 ug/h patch, extended release (transdermal) | Buprenorphine Transdermal System | 5 products, 5 companies | DailyMed |
Its page lists every product and company, the FDA label’s uses and boxed warning, approvals, shortages and recalls: Buprenorphine →
FDA approval
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Holder | First approved | Products |
|---|---|---|---|
| ANDA207490 | Strides Pharma Intl | May 17, 2022 | 5 |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| buprenorphine 20 ug/h patch, extended release | Generic: Buprenorphine Transdermal System | $58.88 per patch Generic of the same strength and form: $58.88 per patch |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list Buprenorphine Transdermal System
The company named on the package (holder, repackager or distributor), as listed in the FDA NDC Directory, with its number of Buprenorphine Transdermal System products.
- Alvogen Inc.4 products
- LTS Therapy Systems, LLC1 product
Recalls
No recall linked to Buprenorphine Transdermal System products (by their NDC code or label) appears in the FDA enforcement reports.
Sources
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug labeling (SPL, openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- NADAC (National Average Drug Acquisition Cost) 2026 — Centers for Medicare & Medicaid Services (CMS), data.medicaid.gov, list of November 4, 2026, retrieved November 7, 2026
Which names get a brand page: a name the NDC Directory lists for a medicine, held by one company (the FDA application holder, or the company named on most of its products), that is not just a description, and that is not the only product of its medicine.